The race is heating up to have a vaccine that go out to the public shortly …
The early one’s are likely to dominate the market next year when there will be mass efforts to distribute the vaccine…
These lead companies will be seeing their stock prices climb on their increased revenue…
One hopes that the vaccine rollouts will drive down the virus infections enough for America and the world to resume some sort normalcy …
This companies actions have been in Britain , Europe and Brazil….
The company is sending it’s results to the American FDA for approval also ….
The drugmaker AstraZeneca announced on Monday that an early analysis of some of its late-stage clinical trials, conducted in the United Kingdom and Brazil, showed that its coronavirus vaccine was 70.4 percent effective in preventing Covid-19, suggesting that the world could eventually have at least three working vaccines — and more supply — to help curb the pandemic.
The British-Swedish company, which has been developing the vaccine with the University of Oxford, became the third major vaccine developer this month to announce encouraging early results, following Pfizer and Moderna, which both said that their vaccines were about 95 percent effective in late-stage studies.
AstraZeneca’s results are a reassuring sign of the safety of the vaccine. It came under global scrutiny after AstraZeneca temporarily paused its trials in September to investigate potential safety issues after a participant in Britain developed a neurological illness.
Oxford and AstraZeneca said they would submit their data to regulators in Britain, Europe and Brazil and seek emergency authorization.
The company said its early analysis was based on 131 coronavirus cases. The trials used two different dosing regimens, one of which was 90 percent effective in preventing Covid-19 and the other of which was 62 percent effective.
AstraZeneca’s vaccine is expected to come with relatively simple storage requirements, which would be an asset once it gets rolled out….
The Brit’s could approve a vaccine’s next month with other European countries to follow right behind….
As G20 leaders pledged to ensure the equitable distribution of Covid-19 vaccines, drugs and tests so that poorer countries are not left out, the US, UK and Germany each announced plans to begin vaccinations in their countries in December, while Spain said it would start administering the vaccine to its citizens in January.
Britain could give regulatory approval to Pfizer-BioNTech’s Covid-19 vaccine as early as this week, even before the US authorises it, the UK’s Telegraph newspaper reported on Sunday. Pfizer and BioNTech could secure emergency US and European authorisation for their Covid-19 vaccine next month after final trial results showed a 95% success rate and no serious side effects.
Moderna last week released preliminary data for its vaccine showing 94.5% effectiveness….
They have a problem ….
The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. “Get yourself a vaccaccino,” a British tabloid celebrated, noting that the vaccine, developed by AstraZeneca and the University of Oxford, costs less than a cup of coffee.
But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine’s apparently spectacular efficacy will hold up under additional testing.
Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results.
Officials in the United States have noted that the results were not clear. It was the head of the flagship federal vaccine initiative — not the company — who first disclosed that the vaccine’s most promising results did not reflect data from older people.
The upshot, the experts said, is that the odds of regulators in the United States and elsewhere quickly authorizing the emergency use of the AstraZeneca vaccine are declining, an unexpected setback in the global campaign to corral the devastating pandemic….